AstraZeneca: China approves use of asthma reliever
(CercleFinance.com) - China has approved the use of AstraZeneca's Symbicort "turbuhaler" as an anti-inflammatory reliever for patients with mild asthma who are 12 years old and above the drugmaker said on Tuesday.
The inhaler, which combines a corticosteroid with a bronchodilator, is the first dual-combination therapy approved in China as an anti-inflammatory reliever to treat mild asthma, the company added.
It was already approved in China for patients with moderate-to-severe asthma as an anti-inflammatory reliever plus maintenance therapy, and as a maintenance therapy only.
Copyright (c) 2021 CercleFinance.com. All rights reserved.